Abstract
Immune checkpoint blockade therapy (ICBT) has revolutionized the treatment and management of numerous cancers, yet a substantial proportion of patients who initially respond to ICBT subsequently develop resistance. Comprehensive genomic analysis of samples from recent clinical trials and pre-clinical investigation in mouse models of cancer provide insight into how tumors evade ICBT after an initial response to treatment. Here, we summarize our current knowledge on the development of acquired ICBT resistance, by examining the mechanisms related to tumor-intrinsic properties, T-cell function, and tumor-immune cell interactions. We discuss current and future management of ICBT resistance, and consider crucial questions remaining in this field of acquired resistance to immune checkpoint blockade therapies.
Funder
National Institutes of Health
Reference84 articles.
1. Aus der Sitzung der medicinischen Section vom 13 November 1867;Busch;Berl. Kli. Wochenschr.,1868
2. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893;Coley;Clin. Orthop. Relat. Res.,1991
3. Cancer immunotherapy comes of age
4. The Basis of Oncoimmunology
5. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献